Fox Chase Cancer Center
Arisaph and Fox Chase Cancer Center are collaborating to screen novel and innovative cancer compounds discovered, designed and synthesized by Arisaph. Specifically, Arisaph has synthesized several ultra-smart pro-drugs, which are designed to yield targeted cancer-cell-killing compounds, and these compounds are currently being evaluated by Fox Chase under the oversight of Dr. Jonathan Cheng, the principal investigator. The Company expects to identify lead candidates and further the development for select cancers.
Fox Chase Cancer Center was founded in 1904 and is an independent, nonprofit institution devoted to improving cancer treatment and prevention. Medical advances based on research are integrated with compassionate care to give patients every possible human and technological advantage in their battles against cancer. Their 100-bed hospital in Philadelphia, PA is one of the largest in the country devoted entirely to cancer care. Fox Chase employs more than 2,100 people and has an annual budget greater than $218 million.
The center's institute for cancer research helped pioneer the modern approach to understanding the disease by bringing together scientists from many disciplines. They study the normal mechanisms of cell growth and the abnormal growth processes of cancer to see what has gone wrong and how it might be corrected. Fox Chase now has more than 80 laboratory research programs.